Welcome to our dedicated page for Ironwood news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood stock.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) is a biotechnology company focused on gastrointestinal (GI) and rare diseases, and its news flow reflects this specialization. Investors and followers of IRWD news will see regular updates on the performance and clinical development of its key assets, particularly LINZESS® (linaclotide) and apraglutide.
News about LINZESS often covers U.S. net sales, prescription demand trends based on IQVIA data, and changes in financial guidance related to collaboration revenue and adjusted EBITDA. Ironwood and its U.S. partner AbbVie share equally in U.S. brand collaboration profits, so quarterly and full-year results frequently highlight LINZESS commercial margin, net profit for the U.S. brand collaboration, and the impact of pricing dynamics, gross-to-net rebate reserves and healthcare policy changes.
For apraglutide, Ironwood’s news includes clinical and regulatory milestones in short bowel syndrome with intestinal failure (SBS-IF). Press releases describe data from the STARS Phase 3 trial and the STARS Extend long-term extension study, including the number of apraglutide-dosed patients achieving enteral autonomy, as well as feedback from the U.S. Food and Drug Administration on the need for a confirmatory Phase 3 trial. Updates on the timing and design of this confirmatory trial and on regulatory submissions are recurring themes.
IRWD news also covers financial guidance for LINZESS U.S. net sales, total revenue and adjusted EBITDA, along with restructuring activities, cost management efforts and strategic reorganization steps. Additional announcements address topics such as Nasdaq listing notifications, changes in the company’s independent registered public accounting firm, participation in investor and scientific conferences, and the ongoing review of strategic alternatives with financial advisors.
By following this IRWD news page, readers can track how Ironwood’s GI and rare disease programs progress over time, how financial expectations evolve, and how regulatory, commercial and strategic developments may influence the company’s outlook.
Ironwood Pharmaceuticals (Nasdaq: IRWD) has announced its upcoming fourth quarter and full year 2024 investor update conference call and webcast, scheduled for Thursday, February 27, 2025, at 8:30 a.m. Eastern Time.
Participants can join via phone by dialing (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID 2530602. The webcast will be accessible through the Investors section of Ironwood's website.
A replay will be available from approximately 11:30 a.m. Eastern Time on February 27 until 11:59 p.m. Eastern Time on March 13, 2025. Replay access numbers are (800) 770-2030 (U.S. and Canada) or (609) 800-9909 (international). The webcast recording will remain available on the company's website for one year after the call.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced significant corporate restructuring and updates on its apraglutide drug development. The company has initiated a rolling NDA submission for apraglutide in short bowel syndrome (SBS), with completion expected in Q3 2025. New data from the open-label extension study showed increased patient success in achieving enteral autonomy.
The company is implementing a 50% workforce reduction, primarily affecting its field force, to optimize costs while maintaining LINZESS growth and supporting apraglutide development. The restructuring is expected to generate $55-60 million in annual operating expense savings.
For FY2025, Ironwood projects LINZESS U.S. net sales of $800-850 million, total revenue of $260-290 million, and adjusted EBITDA exceeding $85 million. The company has also appointed Greg Martini as CFO and Tammi Gaskins as CCO to strengthen its leadership team.
Ironwood Pharmaceuticals (Nasdaq: IRWD) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, December 4, 2024, at 12:30 p.m. ET, taking place at the Lotte New York Palace.
The event will be accessible via live webcast through the Investors section of Ironwood's website. Following the conference, a replay of the fireside chat will be made available on the company's website at www.ironwoodpharma.com.
Ironwood Pharmaceuticals (Nasdaq: IRWD) has announced its participation in the upcoming Jefferies London Healthcare Conference. Sravan Emany, Chief Operating Officer and Chief Financial Officer, will lead a fireside chat on Wednesday, November 20, 2024, at 7:30 a.m. GT at the Waldorf Hilton in London. The event will be accessible via live webcast through the Investors section of Ironwood's website, with a replay available for one year following the conference.
Ironwood Pharmaceuticals reported Q3 2024 results with total revenue of $91.6M, down from $113.7M in Q3 2023. LINZESS prescription demand grew 13% year-over-year, though U.S. net sales decreased 19% to $225.5M. The company maintains its 2024 financial guidance with expected U.S. LINZESS net sales of $900-950M and total revenue of $350-375M. GAAP net income was $3.6M ($0.02 per share) compared to $15.3M ($0.10 per share) in Q3 2023. The company remains on track to complete apraglutide NDA submission in Q1 2025.
Ironwood Pharmaceuticals presented new findings from the STARS Phase III trial of apraglutide at ACG 2024, showing consistent treatment effects across patient subgroups with Short Bowel Syndrome with Intestinal Failure (SBS-IF). The trial met its primary endpoint with a -25.5% vs -12.5% (p=0.001) relative change in weekly parenteral support volume at week 24 vs. placebo.
The analyses demonstrated consistent efficacy across demographics including gender, age, body weight, region, and SBS characteristics. Safety data showed high treatment compliance (>98%) with low incidence of adverse events. Ironwood expects to complete U.S. regulatory submission in Q1 2025.
Ironwood Pharmaceuticals (Nasdaq: IRWD) has scheduled its third quarter 2024 investor update conference call and webcast for Thursday, November 7, 2024, at 8:30 a.m. Eastern Time. Investors can join via phone using conference ID 2530602 or through the company's website. A replay will be available until November 21, 2024, and the webcast recording will be accessible on the company's website for one year after the call.
Ironwood Pharmaceuticals (Nasdaq: IRWD) has announced its participation in the 2024 Wells Fargo Healthcare Conference. The company will engage in a fireside chat on Thursday, September 5, 2024, at 2:15 p.m. ET at the Encore Boston Harbor.
Investors and interested parties can access a live webcast of the fireside chat through the Investors section of Ironwood's official website at www.ironwoodpharma.com. For those unable to attend or watch live, a replay of the webcast will be available on the company's website for one year following the conference.
This participation provides an opportunity for Ironwood Pharmaceuticals to engage with investors and share insights about their business and future prospects in the healthcare sector.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced its Q2 2024 financial results. Key highlights include an 11% year-over-year increase in LINZESS® prescriptions. The company plans to complete the submission for apraglutide's NDA in Q1 2025 and expects CNP-104 topline results in Q3 2024. However, the company revised its FY 2024 guidance due to LINZESS pricing pressures from higher Medicaid utilization. Total revenue dropped to $94.4M from $107.4M in Q2 2023, and GAAP net loss was $860K, significantly improved from a loss of $1.09B year-over-year. Operating expenses were $69.4M, down from $1.19B in Q2 2023. Ironwood ended Q2 2024 with $105.5M in cash and cash equivalents. The company anticipates FY 2024 revenue between $350M and $375M, down from the initial $405M-$425M guidance.
Ironwood Pharmaceuticals (Nasdaq: IRWD) has announced its upcoming second quarter 2024 investor update conference call and webcast, scheduled for Thursday, August 8, 2024, at 8:30 a.m. Eastern Time. Interested participants can join via phone or webcast. The call replay will be available until August 22, 2024, and the webcast archive will be accessible on Ironwood's website for one year after the call.
Key details:
- Conference call-in numbers: (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international)
- Conference ID and passcode: 2530602
- Webcast access: Investors section of www.ironwoodpharma.com
- Replay numbers: (800) 770-2030 (U.S. and Canada) or (609) 800-9909 (international)
FAQ
What is the current stock price of Ironwood (IRWD)?
What is the market cap of Ironwood (IRWD)?
